Increasing diversity in clinical trials for an equitable future

We believe that our research should be equitable and inclusive. That’s especially true for communities that are historically underrepresented in clinical research.

It’s our responsibility to recognize any difference in the safety and efficacy of our drugs and vaccines that may exist between different populations of people.

One challenge is that the vast majority of reported clinical trial participants globally identify as White.^1,2 We are working to ensure our trials are inclusive by design and represent the diversity of the patient populations who are living with the diseases we aim to treat.

Setting targets

We aim to increase, year over year, the diversity of our clinical studies by making meaningful changes that last.

Well before we start a trial, we develop a holistic overview of the patient experience and disease demographics, which forms the basis for our enrollment goals.

Together with input from trusted patient stakeholders within local communities, we apply these insights throughout the clinical trial ecosystem, from protocol development, eligibility criteria, and site selection to recruitment and retention materials.

Making progress in clinical trial diversity

Sanofi is proud to be:

Recognized for our progress by the Bioethics International Good Pharma Scorecard GOLD rating, the highest possible for Diversity, Equity & Inclusion in clinical research

Part of the Beacon of Hope program, a 10-year collaboration with historically Black medical schools in the United States to help achieve greater diversity, health equity, and inclusion of historically underrepresented individuals in clinical trials